Vincerx Pharma, Inc.
0.0320+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · VINC · USD
Key Stats
Market Cap
167.50KP/E (TTM)
-Basic EPS (TTM)
-5.79Dividend Yield
0%Recent Filings
8-K
Vincerx pushes dissolution vote
Vincerx Pharma terminated its Bayer license agreement on June 25, 2025, reverting all licensed IP as it winds down operations ahead of dissolution. Six board members resigned June 30, leaving Acting CEO Dr. Raquel E. Izumi as sole director, with no disagreements noted. The company urges stockholders to approve the July 16 dissolution proposal, estimating $0.04 to $0.08 per share distributions if timely, but warns delays could erase funds via ongoing costs. Bankruptcy looms if approval fails.
10-Q
Q1 FY2025 results
Vincerx Pharma narrowed its Q1 operating loss to $3.3 million from $7.5 million a year earlier, thanks to sharp cuts in research and development spending after a major workforce reduction. Net loss improved to $5.0 million from $12.4 million, though a $1.7 million write-down of a non-recoverable German grant receivable offset some gains; the gap between operating and net loss stems mainly from this charge and prior warrant fair-value swings. Cash dipped to $4.4 million amid $4.5 million in operating outflows, but a $3.9 million at-the-market stock offering cushioned the burn. No debt burdens the balance sheet. Board approved a dissolution plan on April 17, 2025, pending shareholder vote, to wind down operations. Stockholders face minimal distributions, if any, amid creditor claims and wind-down costs.
8-K
Vincerx plans dissolution post-delisting
Vincerx Pharma faces Nasdaq delisting after its stock bid price fell below $1.00 for 30 days, with trading suspended starting April 23, 2025. The board approved a plan to dissolve, liquidate, and wind down operations, seeking stockholder approval to distribute remaining assets post-creditor payments. No appeal planned. Trading resumes briefly April 21-22. Yet distributions remain uncertain amid asset monetization risks.
8-K
Merger terminated, wind-down begins
Vincerx Pharma terminated its non-binding merger letter of intent with QumulusAI on April 7, 2025, scrapping the proposed deal. The board then greenlit wind-down activities while pursuing asset monetization and out-licensing. This pivot signals a strategic retreat. Yet risks loom, including cash shortages and potential bankruptcy.
10-K
FY2024 results
Vincerx Pharma's FY2024 results reflect a strategic pivot amid ongoing clinical efforts, with net loss narrowing to $30.1 million from $40.2 million in FY2023, driven by a 46% drop in research and development expenses to $15.5 million as the company curtailed manufacturing and preclinical work while advancing Phase 1 trials for VIP943 in AML and VIP236 in solid tumors; Q4 saw workforce reductions slashing headcount by 55% to 13 employees, trimming general and administrative costs yet spiking severance to $2.6 million. Cash burn eased to $26.1 million annually, ending with $5.0 million on hand—sufficient into Q3 2025—bolstered by $18.0 million in equity raises, though liquidity remains precarious without new funding. No quarterly breakdowns disclosed, but momentum hinges on monetizing assets like the Bayer-licensed VersAptx platform. Year-end debt is nil, with capex minimal; no dividends or buybacks occurred. Outlook undisclosed, but strategic alternatives including a proposed QumulusAI merger loom. Clinical trial delays from funding shortfalls could derail quarterly progress.
ABVC
ABVC Biopharma, Inc.
2.77-0.13
INBX
Inhibrx Biosciences, Inc.
77.05+8.56
LADX
LadRx Corporation
0.80+0.00
NVCT
Nuvectis Pharma, Inc.
6.77+0.34
NXTC
NextCure, Inc.
11.97+1.62
PCVX
Vaxcyte, Inc.
43.52-1.05
VCNX
Vaccinex, Inc.
0.68-0.04
VIRX
Viracta Therapeutics, Inc.
0.01+0.00
VOR
Vor Biopharma Inc.
25.50-1.43
VTYX
Ventyx Biosciences, Inc.
7.37-0.01